Mark A Healy1, Huiying Yin1, Rishindra M Reddy1, Sandra L Wong1. 1. Affiliations of authors:Department of Surgery (MAH, RMR, SLW) and Center for Healthcare Outcomes and Policy (MAH, HY, SLW), University of Michigan , Ann Arbor, MI.
Abstract
BACKGROUND: Positron emission tomography (PET) scans are often used in cancer patients for staging, restaging, and monitoring for treatment response. These scans are also often used to detect recurrence in asymptomatic patients, despite a lack of evidence demonstrating improved survival. We sought to evaluate utilization of PET for this purpose and relationships with survival for patients with lung and esophageal cancers. METHODS: Using national Surveillance, Epidemiology, and End Results (SEER) and Medicare-linked data, we identified incident patient cases from 2005 to 2009, with follow-up through 2011. We identified cohorts with primary lung (n = 97 152) and esophageal (n = 4446) cancers. Patient and tumor characteristics were used to calculate risk-adjusted two-year overall survival. Using Medicare claims, we examined PET utilization in person-years (to account for variable time in cohorts), excluding scans for staging and for follow-up of CT findings. We then stratified hospitals by quintiles of PET utilization for adjusted two-year survival analysis. All statistical tests were two-sided. RESULTS: There was statistically significant variation in utilization of PET. Lowest vs highest utilizing hospitals performed .05 (SD = 0.04) vs 0.70 (SD = 0.44) scans per person-year for lung cancer and 0.12 (SD = 0.06) vs 0.97 (SD = 0.29) scans per person-year for esophageal cancer. Despite this, for those undergoing PET, lowest vs highest utilizing hospitals had an adjusted two-year survival of 29.0% (SD = 12.1%) vs 28.8% (SD = 7.2%) for lung cancer (P = .66) and 28.4% (SD = 7.2%) vs 30.3% (SD = 5.9%) for esophageal cancer (P = .55). CONCLUSIONS: Despite statistically significant variation in use of PET to detect tumor recurrence, there was no association with improved two-year survival. These findings suggest possible overuse of PET for recurrence detection, which current Medicare policy would not appear to substantially affect.
BACKGROUND: Positron emission tomography (PET) scans are often used in cancerpatients for staging, restaging, and monitoring for treatment response. These scans are also often used to detect recurrence in asymptomatic patients, despite a lack of evidence demonstrating improved survival. We sought to evaluate utilization of PET for this purpose and relationships with survival for patients with lung and esophageal cancers. METHODS: Using national Surveillance, Epidemiology, and End Results (SEER) and Medicare-linked data, we identified incident patient cases from 2005 to 2009, with follow-up through 2011. We identified cohorts with primary lung (n = 97 152) and esophageal (n = 4446) cancers. Patient and tumor characteristics were used to calculate risk-adjusted two-year overall survival. Using Medicare claims, we examined PET utilization in person-years (to account for variable time in cohorts), excluding scans for staging and for follow-up of CT findings. We then stratified hospitals by quintiles of PET utilization for adjusted two-year survival analysis. All statistical tests were two-sided. RESULTS: There was statistically significant variation in utilization of PET. Lowest vs highest utilizing hospitals performed .05 (SD = 0.04) vs 0.70 (SD = 0.44) scans per person-year for lung cancer and 0.12 (SD = 0.06) vs 0.97 (SD = 0.29) scans per person-year for esophageal cancer. Despite this, for those undergoing PET, lowest vs highest utilizing hospitals had an adjusted two-year survival of 29.0% (SD = 12.1%) vs 28.8% (SD = 7.2%) for lung cancer (P = .66) and 28.4% (SD = 7.2%) vs 30.3% (SD = 5.9%) for esophageal cancer (P = .55). CONCLUSIONS: Despite statistically significant variation in use of PET to detect tumor recurrence, there was no association with improved two-year survival. These findings suggest possible overuse of PET for recurrence detection, which current Medicare policy would not appear to substantially affect.
Authors: Lowell E Schnipper; Gary H Lyman; Douglas W Blayney; J Russell Hoverman; Derek Raghavan; Dana S Wollins; Richard L Schilsky Journal: J Clin Oncol Date: 2013-10-29 Impact factor: 44.544
Authors: Michaela A Dinan; Lesley H Curtis; Bradley G Hammill; Edward F Patz; Amy P Abernethy; Alisa M Shea; Kevin A Schulman Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: Bruce E Hillner; Barry A Siegel; Anthony F Shields; Dawei Liu; Ilana F Gareen; Ed Hunt; R Edward Coleman Journal: J Nucl Med Date: 2008-11-07 Impact factor: 10.057
Authors: Bruce E Hillner; Barry A Siegel; Dawei Liu; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman Journal: J Clin Oncol Date: 2008-03-24 Impact factor: 44.544
Authors: Bruce E Hillner; Barry A Siegel; Anthony F Shields; Dawei Liu; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: I Sobhani; E Tiret; R Lebtahi; T Aparicio; E Itti; F Montravers; C Vaylet; P Rougier; T André; J M Gornet; D Cherqui; C Delbaldo; Y Panis; J N Talbot; M Meignan; D Le Guludec Journal: Br J Cancer Date: 2008-02-26 Impact factor: 7.640
Authors: Benjamin L Franc; Robert Thombley; Yanting Luo; W John Boscardin; Hope S Rugo; David Seidenwurm; R Adams Dudley Journal: Breast J Date: 2019-11-18 Impact factor: 2.431
Authors: Nikolai A Podoltsev; Mengxin Zhu; Amer M Zeidan; Rong Wang; Xiaoyi Wang; Amy J Davidoff; Scott F Huntington; Smith Giri; Steven D Gore; Xiaomei Ma Journal: Blood Adv Date: 2018-10-23
Authors: Rory M Shallis; Rong Wang; Jan P Bewersdorf; Amer M Zeidan; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Xiaomei Ma Journal: Ther Adv Hematol Date: 2021-11-30
Authors: Elena Elimova; Rebecca S Slack; Hsiang-Chun Chen; Venkatram Planjery; Hironori Shiozaki; Yusuke Shimodaira; Nick Charalampakis; Quan Lin; Kazuto Harada; Roopma Wadhwa; Jeannelyn S Estrella; Dilsa Mizrak Kaya; Tara Sagebiel; Jeffrey H Lee; Brian Weston; Manoop Bhutani; Mariela Blum Murphy; Aurelio Matamoros; Bruce Minsky; Prajnan Das; Paul F Mansfield; Brian D Badgwell; Jaffer A Ajani Journal: Oncotarget Date: 2017-07-13